Bioequivalence study between a fixed‐dose single‐pill formulation of nebivolol plus hydrochlorothiazide and separate formulations in healthy subjects using high‐performance liquid chromatography coupled to tandem mass spectrometry

Systemic arterial hypertension is a major risk factor for cerebrovascular disease. Therefore, adequate control of blood pressure is of enormous importance. One of the many fixed‐dose single‐pill antihypertensive formulations available on the market is the combination of nebivolol and hydrochlorothiazide. The objective of this study was to develop two distinct high‐performance liquid chromatography coupled to tandem mass spectrometry methods to simultaneously quantify nebivolol and hydrochlorothiazide in human plasma. The methods were employed in a bioequivalence study, the first assay involving a nebivolol fixed‐dose single‐pill formulation based on healthy Brazilian volunteers. Nebilet HCT™ (nebivolol 5 mg + hydrochlorothiazide 12.5 mg tablet, manufactured by Menarini) was the test formulation. The reference formulations were Nebilet™ (nebivolol 5 mg tablet, manufactured by Menarini) and Clorana™ (hydrochlorothiazide 25 mg tablet, manufactured by Sanofi). For both analytes, liquid–liquid extraction was employed for sample preparation and the chromatographic run time was 3.5 min. The limits of quantification validated were 0.02 ng/mL for nebivolol and 1 ng/mL for hydrochlorothiazide. Since the 90% CI for C _max, AUC_(0–last) and AUC_(0–inf) individual test/reference ratios were within the 80–125% interval indicative of bioequivalence, it was concluded that Nebilet HCT™ is bioequivalent to Nebilet™ and Clorana™.     

奈必洛尔的不对称合成

首先合成4-氟-2-(5-羟基戊烷基-3-烯)-苯酚(2), 再经Sharpless不对称环氧化等反应分别得到2-氨基-1-[6-氟- (2S)-3,4-二氢-2H-2-苯并吡喃]-(1R)-1-乙醇(6)和6-氟-2-[(2R)-2-环氧乙烷基]-(2R)-3,4-二氢苯并吡喃(10). 最后, 6和10发生亲核开环反应即得到目标产物奈比洛尔. 整个合成路线简单易行, 并在原有文献的基础上有较大改进, 使收率大大提高, 总收率由文献的2.1%提高到14.1%.     

Rapid and economic chiral-HPLC method of nebivolol enantiomers resolution in dosage formulation

A fast, economic, reproducible, accurate, effective, rugged and selective chiral-HPLC method was developed and validated for the enantiomeric resolution of nebivolol enantiomers [(+)-RRRS and (-)-SSSR)] in dosage formulation. The method was rapid as chiral separation occurred within only 12 min. The mobile phase used was n-heptane-ethanol-DEA (85:15:0.1, v/v) at 3.0 mL/min flow-rate with 225 nm detection. The column used was an amylase-based 3-AmyCoat (150 × 46 mm) [tris-(3,5-dimethylphenyl carbamate)]. The capacity factors of (+)-RRRS and (-)-SSSR enantiomers were 7.85 and 10.90 while the separation and resolution factors were 1.39 and 1.83, respectively. The limits of detection and quantitation for (+)-RRRS enantiomer were 4.5 and 10.00 μg/mL, while these values for (-)-SSSR enantiomer were 4.1 and 8.2 μg/mL, respectively. The linearity was observed in the concentrations range of 0.10-1.0 mg/mL for both enantiomers. The π-π interactions, hydrogen bonds, dipole-dipole interactions and steric effects control the chiral resolution of nebivolol enantiomers on the reported chiral column. The reported method can be used for the quality control of nebivolol in pharmaceutical preparations with good economy. In addition, this method can also be used for the analysis of (+)-RRRS and (-)-SSSR) enantiomers in biological and environmental samples.     

指示稳定性的反相超高效液相色谱评价原料药和制剂配方中奈必洛尔杂质的方法建立与验证(英文)

A sensitive,stability-indicating gradient reverse phase ultra performance liquid chromatographic method has been developed for the quantitative estimation of nebivolol impurities in active pharmaceutical ingredient(API)and pharmaceutical formulation.Efficient chromatographic separation was achieved on an Acquity BEH C18 column(100 mm×2.1 mm,1.7μm)with mobile phase of a gradient mixture.The flow rate of the mobile phase was 0.18 mL/min with column temperature of 30℃and detection wavelength of 281 nm.The relative response factor values of(R*)-2-(benzylamino)-1-((S*)-6-fluorochroman-2-yl)ethanol((R*S*)NBV-1),(R)-1-((R)-6-fluorochroman-2-yl)-2-((S)-2-((S)-6-fluoro-chroman-2-yl)-2-hydroxyethylamino)ethanol((RRSS)NBV-3),1-(chroman-2-yl)-2-(2-(6-fluorochroman-2-yl)-2-hydroxy ethyl amino)ethanol(monodesfluoro impurity),(S)-1-((R)-6-fluorochroman-2-yl)-2-((R)-2((S)-6-fluoro-chroman-2-yl)-2-hydroxyethylamino)ethanol hydrochloride((RSRS)NBV-3)and(R*)-1-((S*)-6-fluorochroman-2-yl)-2-((S*)-2-((S*)-6-fluoro-chroman-2-yl)-2-hydroxyethylamino)ethanol((R*S*S*S*)NBV-2)were 0.65,0.91,0.68,0.92 and 0.91 respectively.Nebivolol formulation sample was subjected to the stress conditions of acid,base,oxidative,hydrolytic,thermal,humidity and photolytic degradation.Nebivolol was found to degrade significantly under peroxide stress condition.The degradation products were well resolved from nebivolol and its impurities.The peak purity test results confirmed that the nebivolol peak was homogenous and pure in all stress samples and the mass balance was found to be more than 98%,thus proving the stability-indicating power of the method.The developed method was validated according to International Conference on Hormonization(ICH)guidelines with respect to specificity,linearity,limits of detection and quantification,accuracy,precision and robustness.